PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, October 22, 2026 at 10:00 a.m. ET to discuss the results of operations for the first quarter of fiscal year 2027, ended September 30, 2026. The call and webcast will follow the release of first quarter fiscal 2027 financial results before the market opens on Thursday, October 22, 2026.

Conference Call and Webcast Details

What: Carpenter Technology First Quarter Fiscal 2027 Conference Call

Date: Thursday, October 22, 2026

Time: 10:00 a.m. Eastern Time

Live Call: +1 833-461-5787

Meeting ID: 956 906 602

Live and Archived Webcast: ir.carpentertechnology.com

About Carpenter Technology

Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, transportation, energy, and industrial and consumer markets. Founded in 1889, Carpenter Technology has evolved to become a pioneer in premium specialty alloys including nickel, cobalt, and titanium and material process capabilities that solve our customers’ current and future material challenges. More information about Carpenter Technology can be found at www.carpentertechnology.com.

Investor Inquiries:   Media Inquiries:
John Huyette Heather Beardsley
+1 610-208-2061 +1 610-208-2278
jhuyette@cartech.com hbeardsley@cartech.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — SLR Investment Corp. (the “Company”) (NASDAQ: SLRC) today announced that it will release its financial results for the quarter ended September 30, 2026 on Tuesday, November 3, 2026 after the close of the financial markets.

The Company will host an earnings conference call and audio webcast at 10:00 a.m. (Eastern Time) on Wednesday, November 4, 2026.

All interested parties may participate in the conference call by dialing (800) 267-6316 approximately 5-10 minutes prior to the call, international callers should dial (203) 518-9783. Participants should reference SLR Investment Corp. and Conference ID: SLRC3Q26. A telephone replay will be available until November 18, 2026 and can be accessed by dialing (800) 839-5247. International callers should dial (402) 220-2703.

This conference call will also be broadcast live over the Internet and can be accessed by all interested parties from the Event Calendar within the “Investors” tab of SLR Investment Corp.’s website, https://slrinvestmentcorp.com/Investors/Event-Calendar. Please register online prior to the start of the call. For those who are not able to listen to the broadcast live, a replay of the webcast will be available soon after the call.

ABOUT SLR INVESTMENT CORP.

SLR Investment Corp. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, the Company primarily invests directly and indirectly in leveraged, U. S. middle market companies in the form of cash flow senior secured loans including first lien and second lien debt instruments and asset-based loans including senior secured loans collateralized on a first lien basis primarily by current assets.

Contact:

SLR Investment Corp.
Richard Pivirotto
646-308-8770

NAPLES, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB:HLYK), a healthcare technology company focused on AI-powered patient engagement, care coordination, and provider connectivity, today announced that it has selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care directly into the HealthLynked mobile application and website, creating a more seamless connection between AI-powered healthcare guidance, provider discovery, appointment scheduling, virtual consultations, and medical record management.

The integration will enable HealthLynked users to access licensed healthcare professionals through secure virtual consultations without leaving the HealthLynked ecosystem. Patients will be able to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual care, and ongoing health management through a single connected platform.

For patients, the integration is designed to reduce the friction of moving between healthcare guidance, finding an appropriate provider, and receiving care by bringing these services together within one HealthLynked experience.

“Healthcare should be convenient, intelligent, and centered around the patient,” said Michael Dent, M.D., Founder and Chief Executive Officer of HealthLynked Corp. “Our partnership with DRCARE247 is an important step in expanding the services available through the HealthLynked platform. By integrating telemedicine directly into the patient experience, we can connect AI-powered guidance with virtual care, provider scheduling, and long-term health management through a single platform. This advances our vision of creating a more connected digital front door to healthcare.”

“At DRCARE247, our mission is to make high-quality healthcare more accessible, convenient, and connected through secure telemedicine services,” said Shafi Ahamed, Head of Business Development at DRCARE247. “We are excited to work with HealthLynked because its integrated platform gives patients a simpler way to discover care, receive AI-powered guidance, and connect with licensed healthcare professionals through virtual consultations. This partnership creates an opportunity to bring DRCARE247’s telemedicine capabilities to more patients while supporting HealthLynked’s vision of a seamless digital healthcare experience. We look forward to working closely with HealthLynked as the platform launches in selected regions and expands access to convenient virtual care.”

HealthLynked’s platform is designed to integrate virtual care into a broader healthcare ecosystem rather than operate as a standalone telemedicine service. The integration is expected to work alongside HealthLynked’s AI-powered patient assistant, enabling patients to receive healthcare guidance, determine when a virtual consultation may be appropriate, and transition directly into telemedicine care. Where clinically appropriate and permitted, patients may also receive prescription management as part of their virtual consultation.

The addition of telemedicine expands HealthLynked’s existing suite of services, which includes AI-driven care navigation, intelligent appointment scheduling, medical record management, provider search, healthcare rewards, prescription savings, enterprise care coordination, and AI-powered patient engagement tools.

Phased Regional Rollout

HealthLynked expects to begin launching the integrated DRCARE247 telemedicine platform in selected geographic regions over the next three months. The phased rollout is designed to optimize the patient experience, provider availability, and clinical workflows before expanding into additional markets across the United States, subject to provider availability and applicable state requirements.

“Our objective is larger than simply offering telemedicine,” added Dr. Dent. “We are building an integrated healthcare platform where patients can receive AI-powered guidance, find and schedule providers, access virtual care, and securely manage their medical records through one connected experience. A phased rollout allows us to optimize the service as we continue to expand the platform.”

The integration expands the range of healthcare services available within the HealthLynked ecosystem and creates additional opportunities for recurring patient engagement. By combining AI-powered navigation, provider connectivity, virtual care, and medical record management within a single platform, HealthLynked is continuing to build a more connected digital healthcare experience for patients and enterprise partners.

About HealthLynked Corp.

HealthLynked Corp. enhances healthcare through personalized care management designed to improve outcomes and reduce costs. Its cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records into one secure, accessible location.

With AI-driven insights, integrated telehealth services, and intelligent patient engagement tools, HealthLynked empowers patients and providers to coordinate care more effectively while delivering savings on prescriptions and healthcare services. The platform supports enterprise partnerships, offering scalable solutions to healthcare networks, employers, insurers, accountable care organizations, and digital health innovators.

Learn more at www.hlykgroup.com

Download the HealthLynked App

Apple App Store
Google Play Store

About DRCARE247

DRCARE247 is a technology-enabled telemedicine provider that connects patients with licensed healthcare professionals through secure virtual consultations. By leveraging digital health technologies, DRCARE247 helps improve access to medical care while providing convenient and efficient healthcare services that can be accessed remotely.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, expectations regarding the integration of DRCARE247’s telemedicine services, the timing and success of the phased regional rollout, anticipated patient adoption, platform utilization, future product enhancements, expansion into additional geographic markets, and the Company’s strategic growth initiatives. Forward-looking statements are based on management’s current expectations and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied. HealthLynked undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor & Media Contact

HealthLynked Corp.
Email: IR@healthlynked.com

InvestorWire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Alignment Health expands into San Antonio, Charlotte and California’s Central Valley, bringing its high-tech, high-touch care model to nearly 9.5 million Medicare-eligible seniors across five states

ORANGE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage (MA) plan from Alignment Health, today announced its 2027 Medicare Advantage portfolio. As many Medicare Advantage plans scale back their geographic footprint, Alignment is doing the opposite. For 2027, the company is expanding into 10 new counties across four states, adding major provider organizations, and introducing new plan options designed to deliver more coordinated, culturally connected care. For 2027, Alignment will offer 77 plans across 55 counties in Arizona, California, Nevada, North Carolina and Texas – a service area that is home to nearly 9.5 million Medicare-eligible seniors, according to Centers for Medicare & Medicaid Services (CMS) data.1

The 2027 portfolio also strengthens Alignment’s provider network in its home market of Southern California, adding Hoag, one of Orange County’s premier health systems, and Astrana Health, a leading value-based care organization whose affiliated medical groups serve Los Angeles, Orange, Riverside and San Bernardino counties – four counties with a combined 3.1 million Medicare-eligible residents.

At a time when many Medicare Advantage organizations are scaling back, Alignment is continuing to grow – entering new markets, expanding provider choice and maintaining a strong portfolio of benefits for the seniors it serves.

“Every senior deserves a health plan that sees them as a person, not a number and provides support throughout their health journey,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “As we expand into new communities in 2027, from San Antonio and Charlotte to California’s Central Valley, we are bringing more than coverage. We are bringing a proven care model, strong provider relationships and personalized support that help seniors get the right care at the right time. Our commitment is simple: make healthcare easier to navigate and help members live healthier, more confident lives.”

Expanding into Major Markets for 2027

Alignment’s 2027 service area grows from 45 to 55 counties. The 10 new counties alone bring more than 934,000 additional Medicare-eligible seniors within reach of Alignment Health’s coordinated care model. New markets, effective Jan. 1, 2027, include:

  • San Antonio, Texas – Alignment Health Plan enters Bexar and Comal counties, its second Texas market after El Paso, with a comprehensive HMO plan, a Smart HMO with a Part B rebate plan, a C-SNP plan and a D-SNP plan. The two counties are home to more than 392,000 Medicare-eligible seniors.
  • Charlotte, North Carolina – Alignment Health Plan expands into Cabarrus, Gaston, Mecklenburg and Rowan counties. These counties encompass more than 295,000 Medicare-eligible seniors and bring Alignment’s North Carolina footprint to 20 counties. Two new plans – a Platinum HMO and a Smart HMO with a Part B rebate – are being introduced exclusively for the Charlotte region, alongside the company’s existing D-SNP and C-SNP plans.
  • California’s Central Valley – Alignment Health Plan adds Kern, Kings and Tulare counties, home to more than 228,000 Medicare-eligible seniors, bringing its California service area to 25 counties. Plan offerings include Platinum and My Choice HMO options. Additional plan options are available for members with heart conditions or diabetes.
  • Nye County, Nevada – The Alignment Health + Intermountain Health co-branded plan extends into Nye County, giving more than 18,000 Medicare-eligible residents access to Intermountain Health’s senior-focused primary care.


What’s New for 2027: Plans and Provider Networks

Beyond geographic growth, Alignment is introducing new plans and network partners designed to give members more choice and more culturally connected care:

  • Expanded access to Hoag in Orange County. Beginning Jan. 1, 2027, Alignment Health Plan members in Orange County will have in-network access to Hoag, a nationally recognized health system with 1,800 physicians, two acute-care hospitals and a broad network of urgent care and outpatient facilities. Access will be available through select plans including the new $0-premium Alignment Health Platinum Preferred (HMO) plan providing members with greater access to high-quality specialty and coordinated care. Orange County alone is home to more than 609,000 Medicare-eligible seniors.
  • Astrana Health expands provider choice across Southern California. Alignment is adding Astrana Health’s vast network of 2,000 primary care providers and 5,000 specialty care providers, initially in Los Angeles, Orange, Riverside and San Bernardino counties. Astrana is a leading value-based care organization with deep roots in Southern California and a longstanding presence in communities served by multilingual, culturally responsive providers who offer care in multiple languages, including English, Chinese and Spanish. Astrana’s emphasis on language access and community-based care supports Alignment Health’s commitment to meeting members where they are and improving access to care for underserved populations.
  • Central Health Harmony (HMO): culturally connected care for Asian American seniors. New for 2027 in Los Angeles and Orange counties, Central Health Harmony provides a comprehensive, culturally connected healthcare experience in Chinese, Vietnamese and Korean, with more than 600 in-language primary care physicians in Los Angeles County and Orange County, including new in-language network partners such as Astrana Health. The plan enhances its complementary care benefits to include acupuncture, cupping, moxibustion, gua sha, tui na and reflexology; adds traditional Asian health and wellness products to its over-the-counter benefit; includes grocery benefits usable at H Mart, TS Emporium, Hannam Chain and Good Fortune Supermarket, subject to plan terms and availability.

Enhanced Pharmacy and Supplemental Benefits

At a time when many seniors are concerned about rising healthcare costs, Alignment continues to offer prescription drug coverage designed to help members manage their medications while keeping out-of-pocket costs low. Members have access to more than 10,000 prescription drug products at a $0 copay across a nationwide network of more than 60,000 pharmacies, and many commonly prescribed medications require no deductible. Members will continue to receive 100-day supplies of many maintenance medications at a $0 copay, including generic medications for diabetes, high blood pressure and high cholesterol. Eligible diabetic supplies and most recommended adult vaccines also remain available at no cost at network pharmacies.

Supplemental benefits are delivered through Alignment’s ACCESS On-Demand Concierge Card. Members can use this single card at more than 70,000 participating retailers for over-the-counter items and, depending on the plan, groceries, utilities, internet and home safety items, with most allowances loaded on the first of each month. Many plans also include a FLEX allowance for dental, vision, hearing, chiropractic, acupuncture and podiatry services; a fitness benefit with access to more than 20,000 gyms and studios at no additional cost; and in-home companion and personal care support of up to 48 hours per year for eligible members.

A Care Model Built Around the Member

Every Alignment Health Plan is backed by the company’s high-tech, high-touch care model, powered by AVA®, Alignment’s proprietary Medicare Advantage technology platform, and supported by clinical and concierge teams available 24 hours a day, seven days a week.

  • 24/7 Concierge Support: Members have around-the-clock access to Alignment team members who can help with benefits, provider searches, care coordination and other healthcare needs in multiple languages.
  • Virtual Care Center: Members can connect with Alignment clinicians 24/7 for urgent health concerns, medication support, health education and other care needs from the comfort of home.
  • Care Anywhere: Members with complex health conditions may receive coordinated in-home and virtual care from Alignment-employed physicians, advanced practice clinicians and care teams.
  • Care Coordination From Day One: New members are offered a comprehensive annual wellness assessment that helps identify health and social needs and creates a personalized care plan to support ongoing care coordination.

Medicare’s Annual Enrollment Period runs Oct. 15 through Dec. 7, 2026, with coverage taking effect Jan. 1, 2027. To learn more about Alignment Health’s 2027 Medicare Advantage plans, visit alignmenthealthplan.com or call 1-888-979-2247.2

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Media Contact:
Jerry Slowey
publicrelations@ahcusa.com

Y0141_27421EN_M

___________________ 

1 Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2026 MA State/County Penetration
2 Alignment Health Plan is an HMO, HMO POS, HMO C-SNP, HMO D-SNP and PPO plan with a Medicare contract and a contract with the California, Nevada, North Carolina and Texas Medicaid programs. Enrollment in Alignment Health Plan depends on contract renewal. The benefit information provided is a summary, not a complete description of benefits. For more information, contact the plan. Call 1-888-979-2247 (TTY: 711), 8 a.m. to 8 p.m. Monday through Friday, for more information. Other providers are available in our network.

New appointment strengthens Vertex’s board with enterprise AI, data, and cloud leadership as the company advances its AI-first transformation

KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced the appointment of Debanjan Saha to its Board of Directors, effective October 7, 2026.

Saha brings more than two decades of experience building and scaling multi-billion dollar agentic AI, data, and cloud businesses in the U.S. and globally. He has served as Chief Executive Officer of DataRobot since September 2022, leading the company’s transformation from a machine learning pioneer to a leader in agentic AI serving enterprise customers worldwide. Previously, he was Vice President and General Manager of Data Analytics at Google Cloud and Vice President and General Manager at Amazon Web Services, where he led the company’s database services. He began his career at IBM in a series of executive and technical leadership roles.

“Debanjan’s experience at the forefront of several major technological transitions, including cloud and now AI, brings the unique perspective that we need to meet the moment,” said Christopher Young, President and Chief Executive Officer at Vertex. “As companies increasingly embed AI into the systems and processes that run their business, that insight will be invaluable to our board and leadership team as we continue building an AI-first company and helping customers transform how indirect tax and compliance work gets done.”

Saha also serves on the board of Sorenson Communications and is a member of its audit committee. He is a Fellow of the Institute of Electrical and Electronics Engineers and a Distinguished Member of the Association for Computing Machinery. He holds Master of Science and Doctor of Philosophy degrees from the University of Maryland and a Bachelor of Technology from the Indian Institute of Technology, Kharagpur, all in computer science.

“Indirect tax touches nearly every enterprise transaction, making it a powerful area to apply AI and unlock new levels of insight, automation, and strategic value,” said Saha. “Vertex has the customer trust, the domain depth, and the global footprint to lead this shift. I’ve spent my career scaling AI organizations through exactly this kind of inflection point, and I’m excited to help the team turn that advantage into category leadership.”

Saha’s appointment expands the Vertex Board of Directors from nine to 10 members, eight of whom are independent. To learn more about Vertex’s Board of Directors and leadership team, visit vertexinc.com/company/our-leadership.

About Vertex  
Vertex is the Decision-to-Defense™ global indirect tax and compliance company. Vertex helps enterprises bring control to indirect tax and compliance across the full transaction lifecycle — from tax determination and e-invoicing through reporting, filing, and audit defense — to make outcomes easier to prove and improve over time. Trusted by more than 60% of the Fortune 500, Vertex combines decades of tax expertise, deep global tax and compliance knowledge, and embedded integrations to help organizations operate globally with confidence. With headquarters in North America and offices in South America and Europe, Vertex’s purpose is to ensure businesses and communities thrive through trusted transactions.

For more information, visit www.vertexinc.com or follow us on X and LinkedIn; or subscribe on YouTube.

Copyright © 2026 Vertex, Inc. All rights reserved. The information contained herein is intended for information purposes only, may change at any time in the future, and is not legal or tax advice. Any product direction and potential roadmap information is not a guarantee, may not be incorporated into any contract, and is not a commitment to deliver any material, code, or functionality. This information should not be relied upon in making purchasing, legal, or tax decisions. The development, release, and timing of any features or functionality described for Vertex’s products remains at the sole discretion of Vertex, Inc. Any statements in this release that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to various risks and uncertainties described in Vertex’s filings with the US Securities and Exchange Commission (“SEC”) that could cause actual results to differ materially from expectations. Vertex cautions readers not to place undue reliance on these forward-looking statements which Vertex has no obligation to update and which speak only as of their dates.

Investor Relations Contact: Joe Crivelli | VP, Investor Relations | investors@vertexinc.com
Vertex Company Contact: Simone Sonnier | Public Relations Manager | mediainquiries@vertexinc.com  

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026.

The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting. IRSF poster presentations are available on Taysha’s website.

Oral Presentation:
Title: Multi-Domain Functional Gains Following TSHA-102 Gene Therapy Across the Rett Syndrome Lifespan: Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts
Date/Time: Thursday, October 15, 2026, 12:30–1:45 PM ET
Presenter: Elsa Rossignol, M.D., FRCP, FAAP, Professor in Neuroscience and Pediatrics at the Université de Montréal, Director of the Rett Multidisciplinary Clinic of the CHU Sainte-Justine and a Principal Investigator of the REVEAL trial

Poster Presentations:
Posters will be presented on Thursday, October 15, from 12:30–1:45 PM ET and from 5:30–7:00 PM ET.

Title: The Developmental Plateau in Rett Syndrome: New Insights from the Natural History Study Inform Novel Interventional Study Designs
Poster Number: 262
Presenter: Minna Montgomery, Medical Office Chief of Staff and Head of Program Management Office, Taysha Gene Therapies

Title: Establishing the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a Primary Endpoint for Interventional Studies
Poster Number: 272
Presenter: Tessa Clarkson, Ph.D., Co-Founder and CEO, Psychlomere, LLC

Title: Multi-Domain Functional Gains Following TSHA-102 Gene Therapy Across the Rett Syndrome Lifespan: Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts
Poster Number: 264
Presenter: Jason Cataldo, D.O., Vice President, Clinical Development and Safety Science, Taysha Gene Therapies

Company-Hosted Symposium:
Title: Rett Syndrome Across the Disease Continuum: From Natural History to Patient-Centered Innovation
Date/Time: Friday, October 16, 2026, 12:00–1:00 PM ET
Presenters:

  • Elsa Rossignol, M.D., FRCP, FAAP, Professor in Neuroscience and Pediatrics at the Université de Montréal, Director of the Rett Multidisciplinary Clinic of the CHU Sainte-Justine and a Principal Investigator of the REVEAL trial
  • Jeffrey Neul, M.D., Ph.D., Director, Vanderbilt Kennedy Center, Annette Schaffer Eskind Chair, Professor at the Vanderbilt University Medical Center, who served as Administrative Head of the Rett Syndrome Natural History Study
  • Tessa Clarkson, Ph.D., Co-Founder and CEO, Psychlomere, LLC

About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Company Contact:
investors@tayshagtx.com

Media Contact:
media@tayshagtx.com

  • 330 patients randomized as of September 30, 2026, surpassing full trial enrollment target
  • Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
  • Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced target of 316 randomized patients. The BACKBEAT Trial is evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication. Hypertension is the most common modifiable risk factor for death worldwide and the most common comorbidity among the pacemaker population.1

The BACKBEAT Trial (NCT06059638) is being conducted with Medtronic plc (“Medtronic”), the Company’s strategic collaborator for the BACKBEAT Trial and, subject to regulatory approval, for the commercialization of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication.

  • As of September 30, 2026, 330 patients have been randomized in the BACKBEAT Trial at 81 sites across 13 countries.
  • The BACKBEAT Trial’s protocol, approved by the U.S. Food and Drug Administration (the “FDA”), specifies 284 evaluable randomized subjects for the primary endpoint analysis, with a total enrollment target of 316 patients to account for potential loss to follow-up.

The BACKBEAT Trial is a global, multi-center, prospective, randomized, double-blind pivotal trial. Patients are randomized 1:1 to AVIM Therapy combined with continued medical therapy and pacing (treatment) or continued medical therapy and standard pacing alone (control). The primary efficacy endpoint of the BACKBEAT Trial is the between-group difference in the change in 24-hour ambulatory systolic blood pressure (“aSBP”) at three-month follow-up from pre-randomization baseline. The primary safety endpoint is freedom from unanticipated serious adverse device events in the AVIM Therapy arm at three-month follow-up. The protocol-specified sample size provides greater than 90% statistical power for both primary endpoints and is designed to detect a between-group difference of at least 5 mmHg in aSBP.

David Hochman, Chairman & Chief Executive Officer of Orchestra BioMed, commented, “Achieving and surpassing full enrollment of the BACKBEAT Trial is a defining milestone for Orchestra BioMed, for our collaboration with Medtronic and potentially for the millions of high cardiovascular risk patients who remain above blood pressure target despite the medications available to them today. We are grateful for and excited about the enrollment momentum built across our global trial site network over the last year. I want to thank the patients and their families who chose to participate, and the clinical teams and investigators at our trial sites globally whose commitment made this milestone possible. Our focus now turns to completing three-month follow-up, database lock, and the delivery of a rigorous, well-powered data set next spring.”

Robert C. Kowal, M.D., Ph.D., Vice President and General Manager for Cardiac Pacing Therapies in the Medtronic Electrophysiology Therapies operating unit, stated, “For decades, cardiac pacing has been foundational in the management of rhythm disorders. Reaching full enrollment in the BACKBEAT Trial brings us a big step closer to understanding whether AVIM Therapy can extend the role of cardiac pacing therapy to include hypertension management for patients at increased cardiovascular risk. We are proud of the collaborative work our team and Orchestra BioMed’s team have done alongside investigators around the world, and we look forward to the primary endpoint results.”

Vivek Reddy, M.D., Executive Chairman of the BACKBEAT Clinical Steering Committee, Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital and Director of Electrophysiology for the Mount Sinai Health System, commented, “Randomized, double-blind evidence is the highest standard by which a new therapeutic modality earns its place in clinical practice, and that is exactly what the BACKBEAT Trial was designed to generate. The pilot data for AVIM Therapy have been exciting, consistent and mechanistically coherent, but the field needs a pivotal trial to answer the question definitively. On behalf of the Steering Committee, I want to recognize the investigators, coordinators and other professionals whose work enabled the trial to reach full enrollment, and I look forward to seeing the three-month primary endpoint results.”

Clinical, Regulatory and Commercial Next Steps

Orchestra BioMed and Medtronic intend to submit the BACKBEAT Trial’s primary endpoint results for consideration as a late-breaking clinical trial presentation at a major cardiovascular conference in the second quarter of 2027. Assuming positive results from the BACKBEAT Trial, Medtronic plans to submit AVIM Therapy marketing applications to the FDA and other global regulatory agencies promptly.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. In MODERATO II, a double-blind, randomized pilot study, AVIM Therapy-treated patients had a mean reduction of 11.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) from pre-randomization baseline at six months, representing a net reduction of 8.1 mmHg versus control patients. At the same time point, the net reduction in office systolic blood pressure (oSBP) was 12.3 mmHg versus control.

Additional MODERATO II data showed an immediate mean oSBP reduction of 13.2 mmHg when AVIM Therapy was activated during setup before randomization, with 97% of patients achieving a reduction of at least 5 mmHg. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics.

The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the timing, implementation, results and design of the Company’s ongoing pivotal trials, the timing of regulatory submissions, realizing the clinical and commercial value of the Company’s product candidates, the potential safety and efficacy of the Company’s product candidates, the size of the potential markets for the Company’s product candidates, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

1 World Health Organization, Global Report on Hypertension 2025 (an estimated 1.4B adults aged 30–79 with hypertension in 2024, 33% of that age group; ~23% of those living with hypertension have their blood pressure effectively controlled).

Clover’s portfolio combines high-choice PPO access and meaningful member benefits with a Clover Assistant-powered care model

WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its 2027 Medicare Advantage (MA) plan offerings, with a continued focus on PPO choice, affordable access to preventive care and meaningful member value. Clover’s Medicare Advantage model is powered by Clover Assistant (CA), which is designed to give physicians across Clover’s broad provider network access to relevant patient information to identify care needs and support better-informed clinical decisions.

Clover Health’s 2027 portfolio provides options for members with different healthcare needs and financial circumstances including:

  • $0 to low premium PPO with broad provider choice and no referrals required*
  • $0 primary care physician (PCP) in-network copays
  • Some of the lowest specialist copays in the industry
  • $0 lab services at preferred providers
  • Routine dental, vision, OTC and gym benefits across all plans
  • Up to $400 in LiveHealthy Rewards for eligible healthy activities
  • Options that pair well with Extra Help/PAAD as well as an MA only plan
  • Clover Assistant-powered care model, designed to help physicians identify care needs and make better-informed clinical decisions

“Medicare Beneficiaries are once again navigating a market where plans are changing, choices can be harder to understand, and affordability matters more than ever,” said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. “Our teams have been deliberate about protecting meaningful PPO choice and access to care for our members, and our ability to pair that flexibility and value with top-ranked clinical quality shows what this model can deliver even as others in the industry pull back.”

High-Choice PPO Access in a Changing MA Market
As MA organizations reassess plan footprints, benefits and distribution strategies, Clover continues to emphasize PPO choice and flexibility. For 2027, Clover will offer a commissionable $0-premium PPO, making it one of relatively few plans to offer this combination in its markets.

Top-Ranked Clinical Quality, Powered by Clover Assistant
Powered by Clover Assistant, Clover’s flagship PPO has ranked #1 nationally among PPO plans on core HEDIS clinical quality measures for two consecutive years, demonstrating the strength of a care model designed to surface relevant information for physicians to identify care needs and support better-informed clinical decisions.1

Clover’s locally focused strategy complements this model. Its 2027 geographic footprint remains consistent with 2026, with New Jersey and Georgia continuing as core markets where Clover is focused on deepening relationships among members, physicians and local healthcare resources.

The 2027 Annual Enrollment Period runs from October 15 through December 7, 2026. Clover Health plans will be available to 5.2 million Medicare-eligible beneficiaries within 203 counties across five states. Plans available based on location are available to view here.

About Clover Health:

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

*Out-of-network/non-contracted providers are under no obligation to treat Clover members, except in emergency situations.

Clover Health is a Preferred Provider Organization (PPO) and a Health Maintenance Organization (HMO) with a Medicare contract. Enrollment in Clover Health depends on contract renewal.

Y0129_26EX091_M

1 This analysis focuses on performance by non-SNP PPO plans with over 2,000 lives as of September 1, 2025 on HEDIS measures applicable to non-SNPs that were used for CMS’s MY 2024 Star ratings, applying the measure ranges used by CMS.

  • Approximately $25 Million Estimated to Reach Start of Production, Down from $40 to $45 Million Previously Estimated
  • First 40 Production Vehicles Planned to Begin Building by the End of 2026; Customer Deliveries for Early 2027, Subject to Timely Financing
  • Approximately $65 Million Estimated to Reach 500 Vehicles Per Month, the Production Rate at Which Aptera Believes It Could Become Self-Sustaining

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Aptera Motors Corp. (Nasdaq: SEV) (“Aptera” or the “Company”), a solar mobility company advancing ultra-efficient transportation, today announced that it now estimates it needs approximately $25 million to reach start of production, down from $40 to $45 million, and approximately $115 million for its full plan through high-volume production, down from $180 to $205 million. The estimated reductions primarily reflect anticipated benefits of the Company’s previously announced partnership with Launch Design (Shanghai Launch Automotive Technology Co., Ltd.).

“This is a fundamentally leaner path to getting Aptera into customers’ hands. We’ve reduced our estimated capital requirements to reach production and brought what we believe could be a self-sustaining business within much closer reach,” said Chris Anthony, Co-CEO of Aptera. “By redesigning the Aptera for manufacturability and tapping Launch Design’s international supplier network, we believe we are pursuing one of the more capital-efficient paths to production in the EV industry.”

The Path to Production

Start of Production. Approximately $25 million, down from $40 to $45 million previously estimated (a reduction of approximately 38% to 44%). This is expected to fund supplier purchases for initial vehicles, remaining tooling, and the final low-volume assembly line in Carlsbad, California. Aptera plans to begin building its first 40 production vehicles by the end of 2026 and to begin customer deliveries in early 2027.

Volume Production Rate. Approximately $65 million in total (about $40 million beyond start of production) to reach 500 vehicles per month, the milestone at which Aptera believes it could fund ongoing operations from vehicle sales.

High-Volume Production. Approximately $50 million more for tooling and equipment to scale toward approximately 20,000 vehicles per year, for a total of approximately $115 million.

All capital and timing estimates depend on Aptera obtaining financing on acceptable terms and on a timely basis, as well as on supplier performance and regulatory approvals.

What Drives the Lower Estimates

The lower estimates principally reflect the expected impact of Aptera’s partnership with Launch Design, including design-for-manufacturing refinements to the vehicle, expected access to Launch’s international supplier network, and a rebuilt bill of materials informed by supplier quotes received to date. Together, these are expected to reduce the estimated full-plan cost by approximately $65 to $90 million, or 36% to 44%, compared with the $180 to $205 million previously estimated.

These updated estimates supersede the capital and timing estimates in Aptera’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

About Aptera Motors Corp.

Aptera Motors Corp. (Nasdaq: SEV) is a solar mobility company driven by a mission to advance the future of efficient transportation. Its flagship vehicle is conceived to be a paradigm-shifting solar electric vehicle that leverages breakthroughs in aerodynamics, material science, and solar technology to pursue new levels of efficiency. As a public benefit corporation, Aptera is committed to building a sustainable business that positively impacts its stakeholders and the environment. Aptera is headquartered in Carlsbad, California. For more information, please visit www.aptera.us.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits of the Company’s strategic partnership with Launch Design, including expectations regarding design-for-manufacturing efficiencies, access to Launch’s international supplier network, bill of materials reductions, and production economics; the Company’s updated capital plan and capital requirements, including the estimated capital required to reach start of production, complete the first 40 production vehicles and commence initial customer deliveries, reach a production rate of 500 vehicles per month, and reach high-volume production; the Company’s expectations regarding self-sustaining operations and its belief regarding the capital efficiency of its plan relative to other electric vehicle companies; the timing and scope of production, including plans to begin building the first 40 production vehicles by the end of 2026 and initial customer deliveries in early 2027; plans to complete final vehicle assembly in Carlsbad, California; the Company’s longer-term production target of approximately 20,000 vehicles per year; and the Company’s financing plans. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall,” “plan,” “continue,” “advancing,” “scaling,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Aptera’s control. These risks include, among others: risks related to Aptera’s ability to raise additional capital on acceptable terms or at all, and the risk that the Company may need to raise additional capital beyond the amounts currently estimated; risks associated with the partnership with Launch Design, including the risk that Launch does not perform as anticipated and that anticipated cost savings, capital reductions, or production timelines are not realized; risks related to reliance on an international supply chain; risks related to tariffs, export controls, trade restrictions, or other changes in U.S. or international trade policy that could affect cross-border manufacturing arrangements; supply chain delays and disruptions, including the risk that suppliers do not perform under purchase orders on the anticipated timeline or at all; the feasibility and timing of scaling our manufacturing and assembly processes; the availability and timing of required capital, and market conditions affecting financing; regulatory approvals and compliance, including regulatory approvals necessary to sell or operate our vehicles commercially; our ability to access capital under our equity line of credit and other sources on acceptable terms and timing; our dependence on successful validation builds and timely component deliveries to achieve any production milestones; risks that actual vehicle demand, pricing and production costs may differ materially from current assumptions; the previously disclosed material weaknesses in our internal control over financial reporting and the timing and cost of remediation; the ongoing SEC investigation; and other risks described in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and our other filings with the Securities and Exchange Commission. Aptera’s ability to continue as a going concern is dependent on its success in raising additional capital and executing its business plan, as further described in its SEC filings. The forward-looking statements included in this press release represent Aptera’s views as of the date of this press release. Aptera anticipates that subsequent events and developments will cause its views to change. Aptera undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Aptera’s views as of any date subsequent to the date of this press release.

Investor Relations:

Aptera Motors Corp.

ir@aptera.us

Media Contact:

media@aptera.us

Regulatory Authorization Supports Deep Isolation’s Plans to Move Its Full-Scale, Non-Radioactive Commercialization Pilot Toward Construction and Field Activities

BERKELEY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that the Texas Railroad Commission has issued a drilling permit for the Company’s full-scale, non-radioactive Commercialization Pilot near Cameron, Texas. The regulatory authorization allows the project to advance from engineering and design toward construction and field activities at the demonstration site.

“Receipt of this permit is a major milestone for Deep Isolation as we move the development of our deep borehole disposal technology into field activities,” said Jesse Sloane, Executive Vice President of Engineering at Deep Isolation. “The Commercialization Pilot is designed to demonstrate, at full scale and at depth, the integrated technologies and operations that underpin our deep borehole disposal solution. Reaching this point reflects a tremendous amount of rigorous, high-quality work by our team and our project collaborators. We are incredibly excited to move into the construction and field work phase together with these collaborators and bring years of engineering and planning into the field.”

“This milestone demonstrates the technical design, project preparation, and collaboration behind the Commercialization Pilot,” said Steve Haden, Senior Vice President, Project Management, at Halliburton. “As we drill a new well for this effort, Halliburton will apply its subsurface, drilling, and well construction experience to support the deployment of Deep Isolation’s technology in a new application and assist the project team.”

The Commercialization Pilot is designed as a full-scale, end-to-end demonstration of Deep Isolation’s deep borehole disposal technology using non-radioactive materials. The project aims to demonstrate key operational activities associated with the Company’s solution, providing field data and operational experience intended to support future commercial deployment.

The Texas project brings together Deep Isolation with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions. With the drilling permit issued, the project team plans to advance site and construction activities in preparation for subsequent drilling and subsurface testing.

Deep Isolation Commercialization Pilot groundbreaking ceremony, Jan. 28, 2026, near Cameron, TX

Deep Isolation Commercialization Pilot groundbreaking ceremony, Jan. 28, 2026, near Cameron, TX

The drilling permit represents another step toward demonstrating how proven drilling practices can be adapted for deep borehole disposal of spent nuclear fuel and high-level radioactive waste. By demonstrating its system at full scale without radioactive material, Deep Isolation aims to generate practical engineering and operational experience that can inform future commercial projects.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. When commercialized, Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is being designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System was developed through a three-year project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy and is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at InvestorRelations@deepisolation.com or CorpSec@deepisolation.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bc0632f5-8e23-44cf-8075-03727209b5c3

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.